Trevena, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2019

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31,
	2019		2018
Compensation and benefits	$	1,786	$	1,524
Restructuring (severance)		—		1,419
Pharmaceutical development expenses		445		231
Accrued interest		18		88
Other accrued expenses and other current liabilities		154		33
Total accrued expenses and other current liabilities	$	2,403	$	3,295